Quick Answer
Anebulo Pharmaceuticals, Inc. reported Net Income of -$8.48 million for fiscal year 2025.
Anebulo Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$8.48M -3.5% |
-$8.20M +30.1% |
-$11.73M -71.9% |
-$6.83M +77.4% |
-$30.25M | — |
| Diluted EPS | -$0.25 +21.9% |
-$0.32 +31.9% |
-$0.47 -262.1% |
$0.29 | — | — |
| Total Assets | $12.15M +198.2% |
$4.07M -65.1% |
$11.67M -25.1% |
$15.58M -28.1% |
$21.65M +615.0% |
$3.03M |
| Cash and Equivalents | $11.63M +275.8% |
$3.09M -72.5% |
$11.25M | — | — | — |
| Stockholders Equity | $11.66M +205.8% |
$3.81M -64.0% |
$10.60M -29.6% |
$15.07M -29.6% |
$21.41M +12611.5% |
-$171.1K |
| R&D Expense | $4.30M +21.2% |
$3.55M -36.6% |
$5.60M +89.1% |
$2.96M +30.5% |
$2.27M | — |
| Operating Income | -$9.22M -11.0% |
-$8.31M +29.5% |
-$11.78M -72.5% |
-$6.83M -89.0% |
-$3.61M | — |
| Shares Outstanding | 41.08M +58.4% |
25.93M +1.2% |
25.63M +9.8% |
23.34M +0.0% |
23.34M +94.5% |
12.00M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | December 31, 2025 | -$2.00M | +18.8% | +7.4% |
| Diluted EPS | December 31, 2025 | -$0.05 | +44.4% | +0.0% |
| Total Assets | December 31, 2025 | $9.42M | -40.5% | -12.0% |
| Cash and Equivalents | December 31, 2025 | $9.04M | -39.7% | -12.7% |
| Stockholders Equity | December 31, 2025 | $7.94M | -47.0% | -18.5% |
| R&D Expense | December 31, 2025 | $1.16M | -4.6% | +43.8% |
| Operating Income | December 31, 2025 | -$2.62M | -1.2% | -15.9% |
| Shares Outstanding | December 31, 2025 | 41.08M | +0.0% | +0.0% |
- Anebulo Pharmaceuticals, Inc. reported Net Income of -$8.48 million for fiscal year 2025.
- Anebulo Pharmaceuticals, Inc. showed a decrease of -3.5% in Net Income compared to the prior fiscal year.
- Anebulo Pharmaceuticals, Inc. reported Diluted EPS of $0.25 per share (loss) for fiscal year 2025.
- Anebulo Pharmaceuticals, Inc. showed an increase of +21.9% in Diluted EPS compared to the prior fiscal year.
- Anebulo Pharmaceuticals, Inc. reported Total Assets of $12.15 million for fiscal year 2025.
- Anebulo Pharmaceuticals, Inc. showed an increase of +198.2% in Total Assets compared to the prior fiscal year.
- Anebulo Pharmaceuticals, Inc. reported Cash and Equivalents of $11.63 million for fiscal year 2025.
- Anebulo Pharmaceuticals, Inc. showed an increase of +275.8% in Cash and Equivalents compared to the prior fiscal year.
- Anebulo Pharmaceuticals, Inc. reported Stockholders Equity of $11.66 million for fiscal year 2025.
- Anebulo Pharmaceuticals, Inc. showed an increase of +205.8% in Stockholders Equity compared to the prior fiscal year.
- Anebulo Pharmaceuticals, Inc. reported R&D Expense of $4.30 million for fiscal year 2025.
- Anebulo Pharmaceuticals, Inc. showed an increase of +21.2% in R&D Expense compared to the prior fiscal year.
- Anebulo Pharmaceuticals, Inc. reported Operating Income of -$9.22 million for fiscal year 2025.
- Anebulo Pharmaceuticals, Inc. showed a decrease of -11.0% in Operating Income compared to the prior fiscal year.
- Anebulo Pharmaceuticals, Inc. reported Shares Outstanding of 41.08 million shares for fiscal year 2025.
- Anebulo Pharmaceuticals, Inc. showed an increase of +58.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: